Journal article · 2026 · Open access

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

Jia Xu, Lin Liu, Wei Xie, Liman Su, Weijiayi Wang, Chenggong Li, Qiaolin Liu, Yun Kang, Yinqiang Zhang, Wenjing Luo, Zhongpei Huang, Chun Zhang and 3 more

Nature Medicine, 32(11), 4117–4126 · Published 6 October 2026 · DOI 10.1038/s41591-026-04704-z

Open PDFView at the publisherCite this paper

In brief

“Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma” is a 2026 journal article by Jia Xu and 14 co-authors, published in Nature Medicine. OpenAlex counts 2 citations as of 17 November 2026, which puts it in the top 5% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.

Citations
2
Most cited in
2026 (2)
Field-weighted impact
4.79
References
43
Authors
15

Abstract

Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodepletion, with up to 3 months of follow-up. The primary endpoints included safety and tolerability, while the secondary endpoints comprised efficacy, pharmacokinetics and pharmacodynamics. All patients developed dual-phase cytokine release syndrome (grades 1-3) and hematotoxicities (grade ≥3). One patient developed grade 1 immune effector cell-associated neurotoxicity syndrome. The objective response rate reached 100% (two stringent complete response and two partial response). Here we update the data on long‑term safety and response durability with a maximal follow‑up of 15 months. No immunogenicity‑ or integration‑related toxicities occurred, and no important adverse events related to ESO-T01 emerged beyond the initial report. Of the four patients, one maintained stringent complete response for 15 months. The median progression-free survival was 4.0 (range 3.0-15.0) months. After progression, diverse salvage therapies extended overall survival to 5.5-10.9 months after infusion. Three patients experienced relapse or progression, all with extramedullary involvement, and eventually died during follow-up. One patient achieved durable response with robust expansion from ex vivo CAR-T. Collectively, these updated results provide additional insights on the safety and efficacy of in vivo CAR-T therapies. The limited persistence observed necessitates the further optimization of the in vivo CAR-T platform. ClinicalTrials.gov identifier: NCT06691685 .

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Xu, J., Liu, L., Xie, W., Su, L., Wang, W., Li, C., Liu, Q., Kang, Y., Zhang, Y., Luo, W., Huang, Z., Zhang, C., Sun, C., Hu, Y., & Mei, H. (2026). Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma. Nature Medicine, 32(11), 4117–4126. https://doi.org/10.1038/s41591-026-04704-z

MLA 9

Xu, Jia, et al. “Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.” Nature Medicine, vol. 32, no. 11, 2026, pp. 4117–4126. https://doi.org/10.1038/s41591-026-04704-z.

Chicago

Xu, Jia, Lin Liu, Wei Xie, Liman Su, Weijiayi Wang, Chenggong Li, Qiaolin Liu, et al. 2026. “Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.” Nature Medicine 32 (11): 4117–4126. https://doi.org/10.1038/s41591-026-04704-z.

Harvard

Xu, J. et al. (2026) ‘Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma’, Nature Medicine, 32(11), pp. 4117–4126. doi:10.1038/s41591-026-04704-z.

IEEE

J. Xu et al., “Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma,” Nature Medicine, vol. 32, no. 11, pp. 4117–4126, 2026, doi: 10.1038/s41591-026-04704-z.

BibTeX

@article{xu2026extended,
  title     = {{Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma}},
  author    = {Xu, Jia and Liu, Lin and Xie, Wei and Su, Liman and Wang, Weijiayi and Li, Chenggong and Liu, Qiaolin and Kang, Yun and Zhang, Yinqiang and Luo, Wenjing and Huang, Zhongpei and Zhang, Chun and Sun, Chunyan and Hu, Yu and Mei, Heng},
  journal   = {Nature Medicine},
  year      = {2026},
  volume    = {32},
  number    = {11},
  pages     = {4117--4126},
  doi       = {10.1038/s41591-026-04704-z},
  url       = {https://doi.org/10.1038/s41591-026-04704-z}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › CAR-T cell therapy research

  • BCMA CAR-T
  • relapsed/refractory multiple myeloma
  • cytokine release syndrome
  • immune effector cell-associated neurotoxicity syndrome
  • CAR T cell persistence
  • long-term safety
  • progression-free survival
  • extramedullary relapse

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Xu, J., Liu, L., Xie, W., Su, L., Wang, W., Li, C., Liu, Q., Kang, Y., Zhang, Y., Luo, W., Huang, Z., Zhang, C., Sun, C., Hu, Y., & Mei, H. (2026). Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma. Nature Medicine, 32(11), 4117–4126. https://doi.org/10.1038/s41591-026-04704-z

How many times has this paper been cited?

2 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Jia Xu, Lin Liu, Wei Xie, Liman Su, Weijiayi Wang, Chenggong Li, Qiaolin Liu, Yun Kang, Yinqiang Zhang, Wenjing Luo, Zhongpei Huang, Chun Zhang and 3 more.

What is the DOI of this paper?

10.1038/s41591-026-04704-z, permanently at https://doi.org/10.1038/s41591-026-04704-z. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.